Systemic delivery of therapeutic viruses

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 4, 2009, Pages 411-420

  Barry, Michael A ^a   Hofherr, Sean E ^a   Chen, Christopher Y ^b   Senac, Julien S ^b   Hillestad, Matthew L ^a   Shashkova, Elena V ^a  

^a MAYO CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biodistribution; Blood cell; Blood coagulation factor; Neutralizing antibody; Systemic delivery; Therapeutic virus

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS; POLYMER; VIROTHERAPY AGENT;

ADENOVIRUS; ADENOVIRUS 5; BINDING AFFINITY; BLOOD CELL; BLOOD GROUP; CELL INTERACTION; CELL MEMBRANE; CELLULAR IMMUNITY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG UPTAKE; GENETIC ENGINEERING; HUMAN; LIVER CELL; LOW DRUG DOSE; NONHUMAN; PROTEIN INTERACTION; REVIEW; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; BLOOD CELLS; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY; MOVEMENT; NEUTRALIZATION TESTS;

EID: 68649085906     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Brunetti-Pierri N, Ng P: Progress and prospects: Gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther (2008) 15(8):553-560.
2. Cattaneo R, Miest T, Shashkova EV, Barry MA: Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol (2008) 6(7):529-540.
3. Reviews the current status of the therapeutic virus field.
4. Nienhuis AW: Development of gene therapy for blood disorders. Blood (2008) 111(9):4431-4444.
5. Robert-Guroff M: Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol (2007) 18(6): 546-556.
6. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replicationconditional herpes simplex virus mutant. J Virol (2000) 74(10):4765-4775.
7. Demonstrates the role of complement in the clearance of HSV after systemic injection.
8. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P, D'Angelo A, Naldini L: A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood (2007) 110(13):4144- 4152.
9. First report of the correction of hemophilia B in mice after systemic delivery of lentivirus vector. Demonstrates miRNA-mediated restriction of transgene expression in off-target cells.
10. Shashkova EV, Doronin K, Senac JS, Barry MA: Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 68(14):5896-5904.
11. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, Subr V, Ulbrich K, Gilbert RJ, Fisher KD, Finberg RW et al: Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackievirus-adenovirus receptor and complement receptor 1. Blood (2009) 113(9):1909- 1918.
12. Describes a barrier to the systemic administration of Ads in humans that is not active in mouse models.
13. Lichtenstein DL, Wold WS: Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: Replication, safety, and transmission. Cancer Gene Ther (2004) 11(12):819-829.
14. Campos SK, Barry MA: Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther (2007) 7(3):189-204.
15. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S et al: Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 78(23):13207- 13215.
16. Chen P, Kovesdi I, Bruder JT: Effective repeat administration with adenovirus vectors to the muscle. Gene Ther (2000) 7(7):587-595.
17. Chen Y, Yu DC, Charlton D, Henderson DR: Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther (2000) 11(11):1553-1567.
18. Dhar D, Spencer JF, Toth K, Wold WS: Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol (2009) 83(5):2130- 2139.
19. Baker AH, McVey JH, Waddington SN, Di Paolo NC, Shayakhmetov DM: The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther (2007) 15(8):1410-1416.
20. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL, Shayakhmetov DM: Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA (2008) 105(14):5483-5488.
21. Elucidates the mechanism of Ad5 transduction of hepatocytes in vivo (see also reference [15]).
22. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J et al: Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 132(3):397- 409.
23. Elucidates the mechanism of Ad5 transduction of hepatocytes in vivo (see also reference [14]).
24. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A: Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 79(12):7478-7491.
25. First report on blood factor binding and the redirection of Ad5 to hepatocytes in vivo.
26. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P, Tordjmann T, Vigne E, Perricaudet M, Benihoud K: Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther (2008) 16(8):1474-1480.
27. Demonstrates that hexon-modified Ad5 efficiently transduces tumors in vivo.
28. Cichon G, Boeckh-Herwig S, Kuemin D, Hoffmann C, Schmidt HH, Wehnes E, Haensch W, Schneider U, Eckhardt U, Burger R, Pring-Akerblom P: Titer determination of Ad5 in blood: A cautionary note. Gene Ther (2003) 10(12):1012-1017.
29. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD: Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther (2006) 14(1):118-128.
30. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A: Adenovirusplatelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol (2007) 81(9):4866-4871.
31. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C, Mennechet F, Schoehn G, Lortat-Jacob H, Dreja H, Ibanes S et al: The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog (2009) 5:e1000277.
32. Demonstrates the CAR-dependent sequestration of CAR-tropic Ads by human erythrocytes (see also reference [8]).
33. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA: Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 18(9):837-848.
34. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D: Adenovirusinduced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood (2007) 109(7):2832-2839.
35. Eggerman TL, Mondoro TH, Lozier JN, Vostal JG: Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation. Hum Gene Ther (2002) 13(1):125-128.
36. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H et al: A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther (2002) 13(1):163-175.
37. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, Chen SJ, Varnavski AN, LeClair C, Raper SE, Wilson JM: Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 3 (5 Pt 1) :708-722.
38. Alemany R, Suzuki K, Curiel DT: Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 81 (Pt 11): 2605-2609.
39. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 3(1):28-35.
40. Smith JS, Xu Z, Tian J, Stevenson SC, Byrnes AP: Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther (2008) 19(5):547-554.
41. Haisma HJ, Boesjes M, Beerens AM, van der Strate BW, Curiel DT, Pluddemann A, Gordon S, Bellu AR: Scavenger receptor A: A new route for adenovirus 5. Mol Pharm (2009) 6(2):366-374.
42. Xu Z, Tian J, Smith JS, Byrnes AP: Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 82(23):11705-11713.
43. Di Paolo NC, van Rooijen N, Shayakhmetov DM: Redundant and synergistic mechanisms control the sequestration of bloodborn adenovirus in the liver. Mol Ther (2009) 17(4):675-684.
44. Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, Muruve DA: The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther (2003) 14(7):627-643.
45. Shashkova EV, Spencer JF, Wold WS, Doronin K: Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther (2007) 15(3):598-607.
46. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE: Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther (2008) 16(6):1073-1080.
47. Compares the biodistribution profiles of AAV serotypes 1 to 9 in mice after intravenous injection.
48. Blankinship MJ, Gregorevic P, Chamberlain JS: Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther (2006) 13(2):241-249.
49. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ: Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol (2001) 75(23):11284-11291.
50. Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM, Randlev B, Patarroyo-White S, Liu T, Smith P, Lehmkuhl H et al: Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol (2005) 79(24):15238-15245.
51. Lilley CE, Branston RH, Coffin RS: Herpes simplex virus vectors for the nervous system. Curr Gene Ther (2001) 1(4):339-358.
52. Whitton JL, Cornell CT, Feuer R: Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol (2005) 3(10):765-776.
53. Kelly EJ, Hadac EM, Greiner S, Russell SJ: Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 14(11):1278-1283.
54. 2 receptor. Proc Natl Acad Sci USA (2006) 103(14):5508-5513.
55. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G: Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol (2008) 82(20):10153-10161.
56. Fukumura D, Jain RK: Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res (2007) 74 (2-3) :72-84.
57. Pruchnic R, Cao B, Peterson ZQ, Xiao X, Li J, Samulski RJ, Epperly M, Huard J: The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther (2000) 11(4):521-536.
58. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M: Pathogen recognition and development of particulate vaccines: Does size matter? Methods (2006) 40(1):1-9.
59. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X: Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol (2005) 23(3):321-328.
60. Identifies AAV8 as the most efficient vector for crossing blood-vessel barriers to deliver therapeutic genes systemically.
61. Hueffer K, Parrish CR: Parvovirus host range, cell tropism and evolution. Curr Opin Microbiol (2003) 6(4):392-398.
62. Hartman ZC, Appledorn DM, Amalfitano A: Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res (2008) 132 (1-2) :1-14.
63. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA: Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther (2000) 1(3):225-235.
64. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE: Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol (1999) 11(4):380-386.
65. Liu Q, Muruve DA: Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther (2003) 10(11):935-940.
66. Yang Y, Su Q, Wilson JM: Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol (1996) 70(10):7209-7212.
67. Waehler R, Russell SJ, Curiel DT: Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 8(8):573-587.
68. Describes strategies to achieve the targeted delivery of therapeutic viruses.
69. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ: Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing Adenoviridae. Science (1999) 286 (5444):1568-1571.
70. Opie SR, Warrington KH Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N: Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 77(12): 6995-7006.
71. Kreppel F, Kochanek S: Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Mol Ther (2008) 16(1):16-29.
72. Comprehensive review of the polymer-coating of Ads.
73. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA: Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther (2008) 16(7):1276-1282.
74. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, Pastore L: PEGylated helper-dependent adenoviral vectors: Highly efficient vectors with an enhanced safety profile. Gene Ther (2005) 12(7):579-587.
75. Gao JQ, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, Yao X, Watanabe H, Asavatanabodee R, Sakurai F, Mizuguchi H et al: Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release (2007) 122(1):102-110.
76. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA: Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gen Ther (2009) :doi:10.1089/hum.2009.028.
77. First report demonstrating the beneficial effect of PEGylation on the safety and anticancer activity of systemically administered oncolytic Ad.
78. Subr V, Kostka L, Selby-Milic T, Fisher K, Ulbrich K, Seymour LW, Carlisle RC: Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release (2009) 135(2):152-158.
79. Describes a novel polymer coating that enabled the detargeting of Ad from blood FX and erythrocytes.
80. Carlisle RC, Benjamin R, Briggs SS, Sumner-Jones S, McIntosh J, Gill D, Hyde S, Nathwani A, Subr V, Ulbrich K, Seymour LW et al: Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med (2008) 10(4):400-411.
81. Espenlaub S, Wortmann A, Engler T, Corjon S, Kochanek S, Kreppel F: Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides. J Gene Med (2008) 10(12):1303-1314.
82. Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S: Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm (2008) 354 (1-2) :3-8.
83. Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH: Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res (2008) 68(7):2071-2075.
84. Munguia A, Ota T, Miest T, Russell SJ: Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 15(10):797-806.
85. Power AT, Bell JC: Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther (2008) 15(10):772-779.
86. Roth JC, Curiel DT, Pereboeva L: Cell vehicle targeting strategies. Gene Ther (2008) 15(10):716-729.
87. Russell SJ, Peng KW: The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther (2008) 10(4):380-386.
88. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 5(3):755-766.
89. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW: Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2007) 14(4): 324-333.
90. Thorne SH, Negrin RS, Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311 (5768): 1780-1784.
91. One of the first studies using cell carriers to improve the systemic delivery of oncolytic viruses.
92. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC: Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 15(1):123-130.
93. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, Diaz RM, Thompson J, Ryno P, Barber GN, Chester J, Selby P et al: Purging metastases in lymphoid organs using a combination of antigennonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2008) 14(1):37-44.
94. Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J et al: Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 15(8):604-616.
95. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol (1997) 71(11):8798-8807.
96. Haisma HJ, Kamps JA, Kamps GK, Plantinga JA, Rots MG, Bellu AR: Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol (2008) 89 (Pt 5) :1097-1105.
97. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB et al: Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 67(19):9398-9406.
98. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H et al: Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 14(1):259-269.
99. Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, McFadden G: Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2008) 16(1):52-59.
100. Dantal J, Soulillou JP: Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med (2005) 352(13):1371-1373.
101. Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K et al: Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 16(7):1217-1226.
102. Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, Selby P, Melcher A, Harrington K, Vile RG: Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide- mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 15(2):561-569.
103. Reports the development of a preconditioning treatment schedule that facilitated the delivery of an oncolytic reovirus to tumors after systemic administration.
104. Nettelbeck DM: Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med (2008) 86(4):363-377.
105. Peled M, Shaish A, Katav A, Greenberger S, Barshack I, Tal R, Bangio L, Breitbart E, Harats D: Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in Cotton rats. Clin Cancer Res (2009) 15(5):1664-1673.
106. Kelly EJ, Russell SJ: MicroRNAs and the regulation of vector tropism. Mol Ther (2009) 17(3):409-416.
107. Comprehensive review of the regulation of vector tropism by RNA interference.
108. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC: A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 16(8):1437-1443.